Platelet to Lymphocyte Ratio Is Associated With the Severity of Coronary Artery Disease and Clinical Outcomes of Percutaneous Coronary Intervention in the Chinese Han Population

Experimental and Therapeutic Medicine - Greece
doi 10.3892/etm.2016.3993
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Association Between Neutrophil to Lymphocyte Ratio and Severity of Coronary Artery Disease

International Journal of Advances in Medicine
2018English

The Link Between Mean Platelet Volume to Lymphocyte Ratio and Complexity of Coronary Artery Disease

Angiology
Cardiovascular MedicineCardiology
2017English

Percutaneous Coronary Intervention for Stable Coronary Artery Disease

Heart
Cardiovascular MedicineCardiology
2018English

Two-Year Clinical Outcomes in Stable Angina and Acute Coronary Syndrome After Percutaneous Coronary Intervention of Left Main Coronary Artery Disease

Korean Journal of Internal Medicine
Internal Medicine
2017English

The Clinical Outcomes of Percutaneous Coronary Intervention in Chronic Total Coronary Occlusion

International Heart Journal
MedicineCardiovascular MedicineCardiology
2006English

Outcomes of Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention With Drug-Eluting Stents for Patients With Multivessel Coronary Artery Disease

Circulation
Cardiovascular MedicinePhysiologyCardiology
2007English

Serum Bilirubin as a Predictor of Coronary Artery Disease Severity in Patients Undergoing Primary Percutaneous Coronary Intervention

World Journal of Cardiovascular Diseases
2019English

Diplotypes of CYP2C9 Gene Is Associated With Coronary Artery Disease in the Xinjiang Han Population for Women in China

Lipids in Health and Disease
BiochemistryEndocrinologyClinical BiochemistryMetabolismDiabetes
2014English

Is Neutrophil-To-Lymphocyte Ratio a Predictor of Coronary Artery Disease in Western Indians?

International Journal of Inflammation
AllergyImmunology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy